Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.32 |
| ▸ | MERTK | Q12866 | 2/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | MAP4K3 | Q8IVH8 | 2/20 | 0.31 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.31 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20193254 | 0.90 | AXL (0.32) | AXLTYRO3MERTKCHUK | |
| SCHEMBL20193216 | 0.90 | CHUK (0.40) | AXLTYRO3MERTKCHUK | |
| SCHEMBL16608283 | 0.89 | DGAT1 (0.33) | AXLTYRO3MERTKFLT3CHUK | |
| SCHEMBL20193156 | 0.87 | GSK3B (0.33) | AXLTYRO3MERTKCHUK | |
| SCHEMBL20193228 | 0.85 | MTOR (0.33) | AXLTYRO3MERTKFLT3CHUK | |
| SCHEMBL20193157 | 0.85 | — | — | |
| SCHEMBL20193218 | 0.84 | GPR119 (0.37) | CHUKMAP3K7TAB1PIK3CAMTOR | |
| SCHEMBL20193213 | 0.82 | GPR119 (0.36) | CHUKPIK3CA | |
| SCHEMBL20193179 | 0.81 | CREBBP (0.32) | TYRO3FLT3CHUK | |
| SCHEMBL19114444 | 0.81 | CHUK (0.33) | AXLTYRO3MERTKFLT3CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981963-B2 | 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |